SCHEMBL2673002

SCHEMBL2673002

Cc1c(Cc2ccc(-c3ccn(C(C)C)n3)cc2)c(OC(F)F)nc2c(Cl)ccc(OC(C(=O)O)(C(C)(C)C)C(C)(C)C)c12

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.32
PPARD Q03181 2/20 0.32
PPARA Q07869 2/20 0.32
P2RX3 P56373 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2573710 0.87 PTGDR2 (0.39) PPARGPPARDPPARAP2RX3
SCHEMBL2572603 0.85 PTGDR2 (0.32)
SCHEMBL2580572 0.84 TGFBR1 (0.32)
SCHEMBL2580577 0.83 TGFBR1 (0.30)
SCHEMBL12167853 0.79 PTGDR2 (0.40) PPARGPPARDPPARA
SCHEMBL3779601 0.77 PPARA (0.39) PPARGPPARDPPARAP2RX3
SCHEMBL2571385 0.74 PTGDR2 (0.41) PPARDP2RX3
SCHEMBL3780751 0.73 TSHR (0.44) PPARGPPARDPPARAP2RX3
SCHEMBL3782820 0.73 P2RX3 (0.36) PPARDPPARAP2RX3
SCHEMBL2573868 0.72 PTGDR2 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173812-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2012-05-08 US disclosed
US-20100144787-A1 Quinolines and Their Therapeutic Use GB005, INC. 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144787-A1 Quinolines and Their Therapeutic Use CHRM3, CHRM2, HRH1 PPARG 1078/4885PPARD 1386/4885PPARA 2270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.